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Abstract 
Over the past 60 years, hyaluronidase has been successfully utilized in ophthalmic surgery and is now being imple‑
mented in dermatosurgery as well as in other surgical disciplines. The enzyme is considered a “spreading factor” 
as it decomplexes hyaluronic acid (also called hyaluronan, HA), an essential component of the extracellular matrix 
(ECM). When applied as an adjuvant, hyaluronidase enhances the diffusion capacity and bioavailability of injected 
drugs. Therefore, the enzyme has been used as a local adjuvant to increase the diffusion capacity of local anesthetics, 
increasing the analgesic efficacy, and the anesthetized area particularly in the first minutes following injection, result‑
ing in diminished intra‑ and postoperative pain. In aesthetic medicine, the off‑label use of hyaluronidase is consid‑
ered the gold standard for the management of HA‑filler‑associated complications. Here, we review the clinical use, 
underlying biological mechanisms, and future directions for the application of hyaluronidase in surgical and aesthetic 
medicine.
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Background
Regulation of hyaluronan (HA) metabolism
The extracellular matrix (ECM) of the skin consists of a 
complex and dynamic network of macromolecules. In 
addition to providing the structural framework, the ECM 
plays an important role in regulating various cellular 
mechanisms including proliferation, adhesion, migra-
tion, and gene regulation [1]. The main components of 
the ECM are the fibrous proteins collagen and elastin, 
as well as, the proteoglycans (PGs) to which character-
istic glycosaminoglycan (GAG) chains are attached. The 
most common GAG in the dermis is hyaluronic acid (also 
called hyaluronan) [2]. Hyaluronan (HA) is a linear gly-
cosaminoglycan disaccharide composed of alternating 
units of n-acteyl-d-glycosamine and d-glucuronic acid 
via alternating β-1.4 and β-1.3 glycosidic bonds [3]. Since 
it is extremely hydrophilic, HA has a high hydration 
capacity and, therefore, contributes to the viscoelastic 
properties of the skin.
Approximately 50 % of all HA in the body is found in 
skin tissue and with typical concentrations ranging from 
0.5 to 1 mg/g in the dermis [3]. Unfortunately, HA con-
tent decreases with age, resulting in loss of skin mois-
ture and laxity, both characteristic features of aging skin. 
Therefore, the cosmetic injection of HA-containing der-
mal fillers has evolved as one of the key strategies in skin 
rejuvenation.
Immunohistochemical analyses of biotinylated HA-
binding proteins demonstrated that HA is not only syn-
thesized by dermal fibroblasts but also by epidermal 
keratinocytes [4]. HA is synthesized by plasma mem-
brane-bound enzymes, the HA synthase enzymes -1, -2, 
and -3 (HAS1-3), that extrude HA directly into the extra-
cellular space. HAS1-3 exhibit distinct enzymatic proper-
ties and synthesize HA chains of various lengths [5].
The turnover of HA depends on location and has an 
approximate half-life in the skin of only one day or less. 
HA is degraded into smaller HA fragments (HAF) by hya-
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hexosaminidic β (1–4) linkages. Depending on the cleav-
age site, HAF size results in either oligosaccharides or 
other larger polymers. In addition, free radicals such as 
reactive oxygen species (ROS) can interact with HA lead-
ing to its degradation. In humans, six HYAL have been 
identified which contribute to this process: HYAL-1, -2, -3, 
-4, PH-20, and HYALP1 [6, 7]. PH-20 is a hyaluronidase, 
specific to the testes and is well known for its essential role 
in fertilization. Localized at the anterior sperm head sur-
face, PH-20 facilitates the penetration of sperm through 
the cumulus cells that surround the oocyte embedded in 
an ECM which is rich in HA [8]. As testicular tissue is a 
physiological source of bioactive hyaluronidase, bovine 
hyaluronidase can be extracted from bovine testes.
The size of HA fragments can vary from high [HMW-
HA; >4  ×  105 Da(lton)] and medium (MMW-HA; 
5 ×  104–4 ×  105 Da) to low (LMW-HA; <5 ×  104 Da) 
molecular weights. Whereas HAS1 and HAS3 syn-
thesize HA fragments of 2 × 105 to 2 × 106 Da in size, 
HAS2 generates HA fragments with approximate sizes 
of 2  ×  106 Da [9]. Interestingly, the molecular size of 
HA appears to be of critical importance for its various 
biological effects [10]. In its high molecular form, HA 
is generally a space-filling molecule that hydrates tis-
sues. Moreover, HMW-HA has been shown to attenuate 
inflammatory responses as it has anti-inflammatory [11], 
anti-angiogenic [12], and also immunosuppressive prop-
erties [13], which suggests that it might play a role in pro-
moting regenerative healing [14]. In addition, Tian et al. 
demonstrated that HMW-HA has intrinsic anti-aging 
and anti-cancer effects [15]. Conversely, LMW-HA has a 
proinflammatory activity. It has been found to be angio-
genic [16], immunostimulatory [17], and inflammatory 
[18]. In addition, McKee et  al. showed that LMW-HA 
increases the expression of macrophage inflammatory 
protein-1a and monocyte chemotactic protein-1, sug-
gesting an important role in proinflammatory responses 
[19], as it may be an important step in the induction of 
the inflammatory cascade.
Hence, HA offers a wide functional spectrum and, 
considering the size-dependent effects, represents an 
important player in the regulation of skin homeostasis. 
However, the underlying mechanisms responsible for the 
size-dependent effects of HA fragments are not clearly 
understood.
In addition to humans, hyaluronidases have been found 
in a variety of venoms from snakes, lizards, and insects. 
In this capacity, they contribute to local damage and 
accelerate the spread of toxins at a bite site and affect the 
local integrity of the ECM due to degradation of HA [20]. 
Moreover, various species of gram positive bacteria (e.g., 
Staphylococcus aureus) are capable of producing bacte-
rial HA lyases as a potential virulence factor to promote 
tissue penetration [21].
Clinical use
In Germany, bovine hyaluronidase (Hylase® Dessau, 
Riemser Pharma GmbH, Greifswald, Germany) is 
approved as an adjuvant for infiltration anesthesia. By 
degrading HA in the ECM, hyaluronidase increases 
membrane permeability, thereby rendering tissues more 
permeable to injected fluids—the so-called spreading 
effect. As a consequence, hyaluronidase reduces viscosity 
of HA which improves tissue diffusion and the resorption 
rate of excess fluids. Co-administration of hyaluronidase 
is a potential option to enhance the effectiveness of local 
anesthesia; increasing the analgesic efficacy with respect 
to the anesthetized area per time (e.g., subcutaneous and 
intramuscular injections) [22]. Indeed, the therapeutic 
application of hyaluronidase has been established in a 
variety of surgical disciplines. In particular, hyaluroni-
dase has been used in ophthalmic surgery for the past 
60  years in combination with local anesthetics for peri-
tubular, retrotubular or sub-Tenon’s anesthesia [23, 24] 
and is now being established in other surgical disciplines, 
including dermatosurgery.
The addition of hyaluronidase to local anesthetics in 
vitreoretinal surgery promotes the dispersion of the local 
anesthetics within the orbit by increasing the surround-
ing tissues permeability. Moreover, hyaluronidase mini-
mizes the increasing orbital pressure associated with the 
volume of injected anesthetics and enhances the quality 
of globe akinesia which reduces the incidence of transient 
postoperative extraocular muscle paresis, as well as, the 
frequency of postoperative pain [25, 26]. In addition, it 
is proposed that the use of hyaluronidase improves the 
operation conditions of eyelid surgery, in particular for 
blepharoplasty [27].
Hyaluronidase treatment and application is generally 
well tolerated and adverse events are rare [28]. However, 
side effects from hyaluronidase use, such as temporary 
postinjection pruritus or allergic reactions, have been 
reported [22, 29]. When the influence of adjuvant hyalu-
ronidase on wound healing was investigated by Wohlrab 
and colleagues using the suction blister method in a pro-
spective, single-center, placebo-controlled, double-blind, 
intraindividual comparison study of 20 participants, 
no retardation of wound healing or other relevant risks 
were observed [22]. These clinical results are in line with 
own (mostly unpublished) in vitro wound-healing analy-
ses, using primary human structural skin cells (primary 
human keratinocytes and dermal fibroblasts).
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Dermatosurgery
In dermatosurgery, the application of hyaluronidase is 
commonly used in regional block anesthesia and in a 
wide variety of other minor surgical procedures. Simi-
lar to findings from ophthalmologic procedures, the 
enzyme contributes to a higher bioavailability of the 
active substance within the target compartment com-
pared to respective controls [29]. Reports on the use of 
hyaluronidase date back as far as 1951, when Thorpe 
noted the beneficial effects of hyaluronidase as an adju-
vant to procaine in “Lancet” [30]. In 1994, Clark and 
Mellette [31] evaluated the effect of combining hya-
luronidase with local anesthesia in 72 operations per-
formed over a 1-year period. The authors concluded that 
benefits of the addition of hyaluronidase to local anes-
thesia included minimization of the loss of surface con-
tour and enhanced ease in undermining and dissection 
through subcutaneous tissue planes [32]. In a prospec-
tive, randomized, placebo-controlled study, Wohlrab 
and colleagues reported that the co-application of hya-
luronidase as a diffusion promotor of lidocaine in sub-
cutaneous application resulted in an expanded effect 
in skin infiltration analgesia in 44 volunteers [33]. In 
1998, Nevarre et  al. showed that the area of anesthesia 
achieved by 1 % lidocaine infiltration can be significantly 
enhanced by the addition of hyaluronidase at a concen-
tration of 15  IU/cc. The authors considered this effect 
to be attributable to the raised pH of the anesthetic area 
to a slightly more physiologic level, resulting in a pH 
closer to that of lidocaine pK and increasing its activity. 
Moreover, co-application of hyaluronidase significantly 
decreased tissue distortion without decreasing the effi-
cacy of anesthetic action. Interestingly, when hyaluro-
nidase was added to 1  % lidocaine, patients indicated 
significantly increased pain at the injection site—an 
aspect which had not been previously reported [33].
In routine clinical practice, hyaluronidase can be used 
as an additive to local anesthetics particularly for pain-
sensitive areas such as the nasolabial fold, upper and 
lower eyelid, ear, lip, mucosa, anorectal, and perianal tis-
sues, as well as, in nail surgery.
Aesthetic dermatology
Progressive loss of dermal HA is one of the hallmarks of 
skin aging. The reasons for the decline in HA are a con-
sequence of both, intrinsic and extrinsic factors, includ-
ing reduced synthesis levels of HA in structural cells, for 
example, in fibroblasts (intrinsic aging) and a progres-
sive degradation of HA due to exogenous stress factors 
such as repeated and extended exposure to UV radiation 
(extrinsic aging) [34, 35].
In addition to its use in local analgesia, the injection of 
HA-based fillers has become increasingly popular over 
the past several years and is now the preferred treatment 
for physicians performing soft tissue augmentations, 
deep skin hydration (native HA or “skin boosters”), or 
facial contouring. One major advantage of HA-based fill-
ers, for example in contrast to calcium hydroxyl apatite-
based (CaHA) or poly-l-lactic acid-based fillers (PLA), 
is the availability of a specific antidote, hyaluronidase, 
which is considered a rescue medication for the manage-
ment of complications resulting from filler injections [36, 
37].
Potential complications of aesthetic filler injections 
include overcorrections, the tyndall effect (bluish dis-
coloration) or lower eyelid edema following tear-trough 
augmentation. Furthermore, granulomatous reactions, 
infections, visual impairment, or even blindness, as well 
as, local tissue necrosis caused by vascular occlusion as 
a result of intravascular HA injections or sidewall com-
pression of vascular structures, can occur. In this con-
text, the title of a review by Hirsch et al. underscores the 
importance of hyaluronidase for aesthetic or corrective 
dermatology: “Hyaluronidase in the office: a necessity for 
every dermatosurgeon that injects hyaluronic acid.” [38]
Recently, we reported on the successful use of hya-
luronidase to reverse a massive HA-injection-induced 
overcorrection of the glabellar rhytide performed by a 
nonmedical practitioner [39]. The infiltrative treatment 
with hyaluronidase resulted in complete remission within 
a few hours. Hence, hyaluronidase has the potency to 
effectively degrade HA-based fillers (Fig.  1). Whether 
this also accounts for all modern HA fillers that may be 
characterized by a high level of cross-linking in order to 
increase duration is currently under debate. Future stud-
ies may test the degradability of HA-based fillers by hya-
luronidase in standardized in vitro and in vivo settings.
Besides overcorrection, the augmentation of the tear 
trough using HA fillers, even when performed by expe-
rienced physicians, is associated with an inherent risk for 
persistent lower eyelid edema which is correlated to the 
high water-binding capacity of HA. In a retroperspective 
analysis of patients presenting with edema following HA 
injection (tear-trough augmentation), we demonstrated 
that hyaluronidase (Hylase® Dessau) injection effec-
tively and rapidly resolved eyelid edema after a single 
injection [40]. Notably, early interventions (within a few 
weeks following development of edema) with hyaluroni-
dase injection were more effective as compared to late 
interventions (after 6  months). For complete remission 
of chronic edema (persistent for more than 6  months), 
often multiple injections of hyaluronidase were required. 
In the clinical practice in respective cases, the injection 
of smaller volumes of hyaluronidase is recommended, as 
larger volumes may not only treat edema but may also 
degrade the effect of augmentation.
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Facial regions prone to vascular side effects following 
dermal HA-filler injections correlate with the anatomy 
of superficial facial arteries. Respective “high risk areas” 
include the glabellar region (supratrochlear artery), the 
nasocilliar region (dorsal nasal artery), the temporal 
region (temporal arteries), the superior nasolabial fold 
and the tear trough (angular artery), or the nasolabial sul-
cus (facial artery). Early signs of vascular complications 
include immediate and severe pain as well as blanching 
due to the interruption of blood flow primarily beyond 
the site of injection. In the course, pain may increase and 
reddish to bluish discolorations of the skin may occur 
which may then progress to tissue necrosis. For the man-
agement of these complications, we recommend immedi-
ate infiltration of the entire area using large volumes of 
hyaluronidase. Hyaluronidase should not only be admin-
istered directly at the site of HA-filler injection, but also 
along the course of the obstructed artery. Importantly, 
direct intra-arterial injection of hyaluronidase is not nec-
essary (or possible). Rather, perivascular hyaluronidase 
will permeate the vascular walls to decomplex intravas-
cular HA. In 2011, Kim et  al. evaluated whether early 
subcutaneous injections of hyaluronidase could decrease 
skin necrosis in HA-induced vascular complications [41]. 
Briefly, the authors used a rabbit ear model in which HA 
filler was injected into the auricular arteries. The authors 
evaluated the efficacy of early (<4 h after HA-filler injec-
tion) vs. late (24  h after HA-filler injection) infiltration 
of hyaluronidase. Interestingly, in the early intervention 
group hyaluronidase significantly reduced the size of 
necrotic areas compared to the late group. Therefore, it 
can be proposed that the injection of hyaluronidase for 
the management of vascular complications following 
HA-filler injections has a higher likelihood of success, 
when performed early (<4 h after HA-filler injection).
In conclusion, we propose the following recom-
mendations for the use of hyaluronidase in aesthetic 
medicine:
  • When working with dermal HA filler, hyaluronidase 
should always be immediately available [38].
  • For aesthetic indications, hyaluronidase (Hylase® 
Dessau) should be dissolved in 1.0 ml saline solution 
(0.9 % NaCl).
  • Severe complications of vascular necrosis following 
accidental intravascular HA-filler injection should 
be immediately treated with infiltrations of large vol-
umes of hyaluronidase in the entire area (ideally <4 h 
post HA-filler injection) [41].
  • For the correction of HA overcorrections, the applied 
volume of hyaluronidase should not exceed the esti-
mated volume of the overcorrection in order to avoid 
complete degradation of the effect of HA augmenta-
tion. Ideally, hyaluronidase should be injected gradu-
ally in small volumes and, when necessary, over mul-
tiple sessions in order to achieve the desired extent of 
correction and to prevent overtreatment [39].
  • For the treatment of lower eyelid edema following 
HA augmentation of the tear trough, only a small 
volume of hyaluronidase should be applied at a time 
Fig. 1 Hyaluronidase effectively degrades hyaluronan‑based dermal fillers. The injection of hyaluronidase results in rapid degradation of the com‑
plex network of hyaluronan (HA)‑fillers into HA fragments
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in order to only gradually dissolve excessive HA and 
to avoid complete reversal of the effect of HA aug-
mentation [40].
  • The efficacy of hyaluronidase treatment in the man-
agement of lower eyelid edema following HA aug-
mentation of the tear trough is more effective when 
applied early (within weeks of the first appearance of 
edema) [40].
Open questions and perspectives
Today, the molecular and cellular mechanisms of HA 
catabolism within the ECM and in particular hyaluroni-
dase-HA interactions have remained largely unknown. 
Frequently asked questions include: Does medical appli-
cation of hyaluronidase influence postoperative wound 
healing and repair? Does clinical hyaluronidase-mediated 
HA degradation in the management of HA overcorrec-
tions also impair the skin´s physiological HA production? 
Does the application of hyaluronidase interfere with the 
natural aging process of the skin?
In this context, we can propose that our own, yet 
unpublished, in  vitro experimental data show that 
bovine hyaluronidase (Hylase® Dessau) does not neg-
atively influence wound healing in a monolayer of 
primary human keratinocytes and primary human 
fibroblasts. In addition, we can propose that bovine hya-
luronidase significantly and dose-dependently induces 
the synthesis of HA in structural skin cells. Degrada-
tion of body’s own HA by injection of hyaluronidase 
will therefore be immediately replaced by de novo syn-
thesis of HA in fibroblasts (see Fig. 2). To what extent, 
however, the infiltration of excessive volumes of hyalu-
ronidase may result in a temporary HA deficit due to a 
limited capacity of concurrent synthesis of HA remains 
a matter of debate. Clearly, in addition to excessive der-
mal HA filler, the exogenous administration of hyaluro-
nidase will also decomplex naturally derived HA within 
the ECM.
Finally, besides its high potential in both surgery and 
aesthetic medicine, hyaluronidase has already been 
established in the management of extravasation of cyto-
static drug infusion, as a therapeutic option in fibrotic 
diseases and for faster subcutaneous liquid absorption 
in pediatrics [29, 42]. In addition, subcutaneous applica-
tion of monoclonal antibodies in combination with hya-
luronidase also appears to be promising. Currently, the 
anti-HER2-antibody Trastuzumab (Herceptin® SC) and 
anti-CD20-antibody Rituximab (MabThera® SC) are used 
along with hyaluronidase as an excipient in subcutaneous 
(SC) formulations [43].
Conclusion
In recent years, hyaluronidase has been well established 
in ophthalmic surgery as well as, in dermatosurgery. In 
Fig. 2 Degradation of dermal hyaluronan by infiltration of hyaluronidase. Dermal fibroblasts play a major role in neo‑synthesis of hyaluronan (HA) 
as an essential component of the extracellular matrix (ECM). The injection of hyaluronidase degrades HA, and subsequently renders the ECM more 
permeable, resulting in a greater diffusion capacity and bioavailability of injected drugs. In addition, applied hyaluronidase induces the de novo 
synthesis of HA in dermal fibroblasts to compensate potential transient hyaluronidase‑induced HA deficits
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aesthetic medicine, the use of hyaluronidase is con-
sidered as the gold standard for the management of 
complications of HA fillers and should be immediately 
available at every treatment. Further clinical and experi-
mental studies may provide greater insights as to new 
and diverse therapeutic applications for hyaluronidase in 
clinical practice in the future.
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